Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo. ^[1] Researchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes. ^[2] A new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses. ^[3] Some emerging treatments were associated with weight loss exceeding 20% of body weight. ^[4] The review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults. ^[5] By comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial. ^[6] Low-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide. ^[7]